The virtual lack of well-characterized metastatic pancreatic cancer tissues for study has limited systematic studies of the metastatic process of this deadly disease. To address this important issue, we have instituted a rapid autopsy protocol for the collection of high quality tissues from patients with metastatic pancreatic cancer, called the Gastrointestinal Cancer Rapid Medical Donation Program (GICRMDP). At the time of preparation of this manuscript, 20 patients with metastatic pancreatic cancer and one patient with metastatic colon cancer have undergone a rapid autopsy in association with the GICRMDP. The average time interval achieved for these 21 patients was 8.0 hours, with more than 500 individual samples of matched high quality primary and metastatic pancreatic cancer tissues, peritoneal/pleural fluid and blood obtained so far. For the first four patients in which the autopsy was performed in <6 hours, we have successfully xenografted the primary tumor and/or two to four independent matched metastases from a variety of target organ sites, with a take rate of almost 60% for the first 26 xenografted tumors attempted. In an initial survey of KRAS2, TP53 and DPC4 genetic status in lethal metastatic pancreatic cancers, activating KRAS2 mutations were detected in 82% of cases and inactivating TP53 mutations in 55% of cases, consistent with rates of genetic alteration of these genes in early stage pancreatic cancers. However, DPC4 inactivation was found in 75% of patients analyzed, suggesting that genetic inactivation of the DPC4 tumor suppressor gene continues to be selected for with growth at the primary site and metastatic spread to other organs. The invaluable tissue resources generated by the success of the GICRMDP will provide an unparalleled resource for study of metastatic pancreatic cancer and of the metastatic process in general.
INTRODUCTION
Pancreatic cancer is an almost uniformly lethal disease. In the year 2003 in the United States, an estimated 31,000 patients were diagnosed with pancreatic cancer, and an estimated 31,000 patients died of pancreatic cancer. 1 The dismal prognosis associated with pancreatic cancer is largely due to the fact that most patients are diagnosed at an advanced stage of disease. Eighty percent of patients with pancreatic cancer are not candidates for surgical resection because they have metastatic disease at the time of diagnosis, and 70% of patients who undergo surgical resection are found to have metastases in their resection specimen. 2 It should not be surprising that virtually all patients with pancreatic cancer will die of metastatic disease. 3 Chemotherapy and radiotherapy are of limited benefit to patients with metastatic pancreatic cancer. Gemcitabine is the current standard of care for patients with advanced disease, but has shown clinical responses in a minority of patients. [3] [4] [5] Clinical trials to determine the utility of adding a second cytotoxic drug or radiotherapy to this treatment regimen have shown modest improvements in disease-free survival, with reported survival rates reaching 20-40% at one year. 3, 6 Clearly, a better understanding of metastatic pancreatic cancer is urgently needed if we are to have an impact on patient survival.
Dramatic advances in our understanding of the molecular biology of pancreatic carcinogenesis have occurred within the past decade. Early studies of pancreatic cancer identified chromosome arms 9p, 18q, 17p, 1p and 6q as having high rates of allelic loss in a series of xenografted primary infiltrating pancreatic cancers. 7 Based in part on these findings, the tumor suppressor genes p16 (CDKN2A) on chromosome 9p, DPC4 (SMAD4, MADH4) on chromosome 18q, MKK4 on chromosome 17p, STK11/LKB1 on chromosome 19p, and BRCA2 on chromosome 13q were identified as inactivated in primary pancreatic cancers. 8 Most recently, genetic inactivation of members of the Fanconi's Anemia gene family have been identified in primary infiltrating pancreatic cancers with important implications for chemotherapeutic responses to mitomycin C in a subset of patients with these mutations. 9, 10 While it is evident that the above described findings regarding primary pancreatic cancer represent significant advances in our understanding of this disease, these studies have all been performed on surgically resectable primary pancreatic cancers and thus represent the minority of patients diagnosed with pancreatic cancer. Moreover, the virtual lack of well-characterized metastatic pancreatic cancer tissues for study has limited systematic studies of the metastatic process. To approach these important issues, we have instituted a rapid autopsy protocol for the collection of high quality tissues from patients with metastatic pancreatic and colorectal cancer, called the Gastrointestinal Cancer Rapid Medical Donation Program (GICR-MDP). This program is similar to other rapid autopsy programs for the study of metastatic prostate cancer. 11 Preliminary findings on patient recruitment, clinicopathologic features of metastatic disease, and the rates of xenograft formation are presented, as well as initial data regarding the rates of KRAS2 activation and TP53 and DPC4 genetic inactivation of lethal metastatic pancreatic cancers. is eligible to participate. Patients are recruited directly from the medical and radiation oncology clinics at The Johns Hopkins Hospital (D.L., M.H.) or are self-referred through the Johns Hopkins Pancreas Cancer Web Page (http://pathology2.jhu.edu/pancreas/endoflife). For those patients identified through the oncology clinics, the decision to discuss participation in the study is based on a strong physician-patient relationship and on the clinician's assessment of the patient's emotional status. Once a patient is referred to the GICRMDP, appropriate verbal and written information about the study are provided, and informed consent is obtained to perform a rapid autopsy and to obtain copies of all past medical records and previously removed surgical tissue. When possible, discussion of the study and informed consent takes place with the patient's spouse and/or next of kin present. Final permission for autopsy remains in the hands of the patient's next of kin at the time of death. The patient's next of kin immediately notify the GICRMDP team when the patient died. All members of the team are on call 24 hours a day/ 7 days a week at the time of an impending autopsy.
MATERIALS AND METHODS

Recruitment
Performance of the rapid autopsy. Performance of the rapid autopsy procedure at The Johns Hopkins Hospital follows an organized team approach. The team includes a board-certified pathologist (C.I.D. or G.S.B.) and physician assistant (K.F.) for harvesting of all normal and cancer tissues and four additional team members (E.E.E., S.dB.W., F.R., K.J.Y.) responsible for tissue processing, labeling and xenografting of selected neoplastic tissues.
The tissue harvesting protocol consists of the following; after opening of the body cavity using standard techniques, approximately 50% of the primary neoplasm and each grossly identified metastasis are sampled using a sterile blade and forceps (one set per tumor) with care to avoid areas of grossly evident necrosis or hemorrhage. Tumor tissues are sliced into 1.0 x 1.0 x 0.2 cm sections for overnight fixation in 10% buffered-formalin or 75% 3:1 ethanol:methanol for paraffin-embedding, for freezing in OCT media in liquid nitrogen and storage at -80˚C, or for snap-freezing in liquid nitrogen in 1.5 ml cryovials and storage at -80˚C. For those patients in which peritoneal ascites and/or pleural effusions are present, 50 mls of each are collected under sterile conditions and stored at -80˚C. In all cases, samples of normal liver, lung and spleen are also harvested for processing as described above, as well as 10 mls of whole blood from the right atrium.
In the case of a self-referred patient who died in a geographic location not amenable to transport to The Johns Hopkins Hospital, the tissue harvesting and autopsy procedure are performed at a local hospital by a certified pathologist that is arranged in advance in collaboration with the GICRMDP. In these cases a limited harvesting is performed in which each sample of the normal, primary and/or metastatic tumor tissues is bisected for both snap-freezing on dry ice and fixation in 10%-buffered formalin.
In all cases, tissue harvesting is followed by a standard complete diagnostic autopsy minus any restrictions specified in the consent form. The unique identifier of each sample assigned at autopsy is entered into an Access relational database including all clinicopathologic information related to the patients medical and surgical history, medications, imaging studies, pathology and autopsy findings.
Creation of pancreatic cancer xenografts. For those patients in which the rapid autopsy is performed at The Johns Hopkins Hospital and the ischemic interval is <6 hours, two to three mm 3 samples each of the primary infiltrating carcinoma and 4-8 different metastases are placed into sterile RPMI media (Invitrogen, Carlsbad, CA) for transport to the animal facility for xenografting into CD1 nu/nu mice. In all cases, care is taken to obtain grossly viable tissue. Xenografting is performed as described by Hahn et al. 7 Tumor tissues are minced with a sterile blade into 1 mm 3 pieces in Matrigel (Becton Dickinson, Bedford, MA), and one to two mm 3 of tissue are implanted beneath the skin fold of the shoulder bilaterally while the mice are under isoflurane inhalation anesthesia. The implantation site is closed with a single 6.0 chromic suture. The animals are followed weekly for growth of xenografts, and the xenografts are harvested when they reach 1.0-1.5 cm in size. The harvested tumors were stored at -80˚C, and a small piece of the xenografted tumor (1-3 mm 2 ) is implanted into a new mouse to perpetuate the xenograft.
Tissue microdissections. For pancreatic cancers in which xenograftenriched tumors were not available, microdissection of the primary or metastatic carcinoma tissues was performed to enrich for neoplastic cells as previously described. 12, 13 Only samples in which at least 50% neoplastic cellularity could be obtained were used for genetic studies.
PCR and sequencing of KRAS2, p53 and DPC4. Genomic DNA was extracted from xenograft enriched or microdissected pancreatic cancers using DNeasy kits (Qiagen, Valencia CA). PCR amplification of exon 1 of KRAS, exons 5-9 of TP53 and exons 1-11 of DPC4 from genomic DNA was performed as described. 12, 14, 15 PCR-amplified products were purified using QIAquick columns (Qiagen) and studied by automated sequencing using nested primers and an ABI Prism model 3700 (Applied Biosystems, Foster City, CA). Sequence analysis employed Sequencher™ version 4.0.5 software (Gene Codes, Ann Arbor, MI). Verification of the mutation was accomplished by sequencing of a second PCR product derived independently from the original template.
Immunohistochemistry for Dpc4 protein. Formalin-fixed tissues from each patient who participated in the GICRMDP were paraffin-embedded following standard techniques. Archival samples of metastatic pancreatic cancer from 19 patients were also obtained from the Autopsy Pathology Files of The Johns Hopkins Hospital as previously described. 16 For all cases, unstained 5-Μm sections were cut from the paraffin blocks and deparaffinized by routine techniques followed by steaming in sodium citrate buffer pH 6.0 for 20 minutes at 80˚C. Slides were cooled 15 minutes and incubated e13
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RESULTS
Clinicopathologic characteristics of patients. A summary of the first 21 patients to undergo an autopsy as part of the GICRMDP is shown in Table 1 . The mean age is 65.4 ± 8.1 years, sixteen patients were male and five were female. All 21 patients were Caucasian. Seventeen patients had clinically evident metastatic disease at the time of diagnosis (clinical stage IV), and four patients underwent pancreaticoduodenectomy at the time of diagnosis (clinical stage III, patients A16, A19, A20, A21) but later developed local recurrence and metastatic disease. The mean time from diagnosis to death was 16.0 months (range 0.5-45 months).
The mean time interval from death to autopsy for all cases was 8.0 hours (median 3 hours, range 1-24 hours). Delays in performance of the autopsy (>6 hours) were in all cases due to unavoidable limitations in transportation to the facility where the procedure was performed. In all cases, the gross and histologic examination of the autopsy tissues confirmed the diagnosis of primary infiltrating pancreatic or colonic adenocarcinoma. Among the 20 patients with pancreatic adenocarcinoma, 16 primary cancers were localized to the head of the pancreas, 3 to the tail, and 1 diffusely involved the entire gland. Eighteen carcinomas were poorly differentiated, 1 carcinoma was poorly differentiated with foci of mucinous differentiation, and 1 carcinoma was moderate to well differentiated with mucinous features.
Patterns of advanced disease in patients with terminal pancreatic cancer. The patterns of metastatic spread of pancreatic cancer have been reported in several large retrospective studies. 17, 18 Our findings of the metastatic pancreatic cancer disease burden in these 20 patients are consistent with those reports. Gross evidence of metastatic disease was present in 17 of 20 patients, with a mean of 2.9 ± 2.8 target organs involved. As expected, the organ most commonly involved by metastatic disease was the liver (16 of 17 patients, 94%), followed by the lungs (8 of 17 patients, 47%), abdominal lymph nodes (7 of 17 patients, 41%) and peritoneum/omentum (7 of 17 patients, 41%). The thoracic lymph nodes (5 of 17 patients, 29%) and adrenal glands (4 of 17 patients, 21%) were involved in a subset of patients, whereas the cardiovascular, reproductive and genitourinary systems were the least frequently involved sites in this set of patients. In one patient (A8), the lungs and the para-aortic lymph node chain were the predominant site of metastasis, with no gross evidence of disease noted in the liver.
Creation of xenografted tumors from autopsy tissues. In addition to our goal of obtaining well-characterized high quality tissue from patients with metastatic pancreatic cancer for research purposes, we have successfully created xenografted tumor tissues for use in in-depth studies of the molecular genetics associated with pancreatic cancer metastasis ( Table 2 and Fig. 1 ). For five patients in which the rapid autopsy was initiated <6 hours (A2, A5, A6, A10 and A13), samples of the primary and/or metastatic tumor tissues were xenografted into nude mice. A total of 30 individual tumor tissues were xenografted from these patients representing the five primary carcinomas and 24 different metastases. Two mice died shortly after the xenografting procedure, leaving 28 mice for study. Using one mouse per tumor and two insertion sites per mouse, 16 of these 28 tumors (57%) were successfully grown as xenografts in nude mice, representing three different primary tumors and twelve different metastases. The mean time from implantation to harvesting for these 16 xenografted tumors was 4.4 ± 1.2 months.
Mutations of KRAS2, TP53 and DPC4 in metastatic pancreatic cancers. The ultimate goal of the GICRMDP is to determine the molecular or genetic events associated with lethal cancer metastasis. Towards this end, we performed a survey of KRAS2, TP53 and DPC4 genetic alterations among a subset of our cases for which high quality genomic DNA with at least 50% neoplastic cellularity could be achieved (Table 3) . Twenty-six samples were analyzed from 11 patients representing six primary carcinomas and twenty different pancreatic cancer metastases. For seven of these 11 patients, two to four different metastases were analyzed.
Activating mutations of KRAS2 and inactivation of TP53 are among the most common genetic events in pancreatic carcinogenesis. 14 mutations of KRAS2 were found in nine of 11 (82%) patients' tumors, in all cases at codon 12, while inactivating mutations of TP53 were found in six of 11 (55%) patients cancers within the evolutionarily conserved domain. 14 In all seven cases in which more than one sample from a patient was analyzed, the KRAS2 or TP53 mutations were concordant in both the primary carcinoma and/or all matched metastases (Table 3 ). All mutations originally found in xenografted tumors (patients A2, A6, A10 and A13) were confirmed in genomic DNA obtained from microdissection of the original cancer tissues from which the xenografts were derived. In two cases (A14 and A15), no mutations were found of KRAS2 or TP53 despite PCR amplification of genomic DNA obtained from two or more independent microdissections of high quality tissue. DPC4 is a tumor suppressor gene inactivated in ~55% of surgically resected pancreatic cancers analyzed. 15 As the predominant mechanism of DPC4 inactivation is by homozygous deletion, 21 screening for genetic deletions by amplification failure is not possible using microdissected tissues as normal cellular DNA within the sample may amplify and obscure findings. To account for this possibility, we performed whole gene sequencing of DPC4 together with immunohistochemical labeling for Dpc4 protein in the same tissues. Immunolabeling for Dpc4 protein in paraffin-embedded tissues has been described as a reliable marker of the genetic status of the DPC4 gene. 22 Among the four xenograft enriched carcinomas homozygous deletion of DPC4 was found in three of four cases. These three cancers were also negative for Dpc4 labeling (cases A2, A6, and A10), while the one case without a deletion or intragenic mutation showed strong positive labeling for Dpc4 protein (case A13) (Fig. 2) . Among the seven patients for which only microdissected material was available, no intragenic mutations were found within the entire coding region. However, all seven carcinomas showed complete loss of immunohistochemical labeling for Dpc4 protein consistent with a deletion of DPC4. When combined with the four xenograft enriched carcinomas, Dpc4 inactivation was found in 10 of 11 patient's primary and/or metastatic carcinomas (91%).
To rule out that the higher rate of DPC4 inactivation was not related to the number of patients analyzed, we determined the Dpc4 immunolabeling patterns among an additional six patients from the GICRMDP for which high quality tissues were available, as well as the archival material from an additional 19 patients with widely metastatic pancreatic cancer from the Autopsy Files of The Johns Hopkins Hospital. When combined with the original 11 patients, loss of Dpc4 immunolabeling was noted among 13 of 17 (76%) patients' metastatic pancreatic cancer tissues obtained from the GICRMDP, and among 14 of 19 (71%) patients metastatic disease obtained from the archival materials. A comparison of the frequency of Dpc4 loss in surgically resectable pancreatic carcinomas reported by Wilentz et al. 23 
DISCUSSION
In order to evaluate the importance of cellular changes already described in pancreatic cancer, and to provide a solid foundation for future studies of metastatic pancreatic cancer, it is absolutely critical to study pancreatic cancers that have already caused significant morbidity and mortality. The primary source of such material is through the autopsy of men and women who have died from metastatic pancreatic cancer. The high-quality tissues obtained through the successful establishment of the GICRMDP, in addition to the ability to create xenografted tumors, will permit a similar quality of analyses of metastatic pancreatic cancer as shown for surgically resected disease, including the genetic alterations associated with pancreatic cancer metastasis or the molecular biologic correlates of adjuvant therapy failure, among others.
Although this study represents a preliminary survey of metastatic disease spread, we have noted differences in disease burden that related in part to the cause of mortality, similar to that described by Nakahashi et al. 24 Specifically, four patients (A2, A6, A17 and A21) demonstrated extensive metastatic involvement of the liver so that death resulted directly from hepatic failure. In contrast, for eight patients the cause of death related to marked extension of the primary tumor into adjacent vital structures (ex. A1, A3, A5, A7, A8, A11, A12, A15), despite a wide range of metastatic spread to other sites. Finally, for six patients, no obvious relationship between disease www.landesbioscience.com
Cancer Biology & Therapy e16 burden and cause of death was found. In these cases, morbidity and mortality appeared related to generalized multiorgan failure and cachexia (ex. A9, A10, A13, A18, A19, A20). For two patients, the ultimate cause of death was unknown or unrelated to their disease (A14 and A16). The availability of the complete treatment history for each of these patient included in the study provides an invaluable opportunity to correlate these observations with chemotherapeutic history. Additional studies of the metastatic process with respect to these patterns of growth will determine the significance, if any, of these observations. The utility of xenografted tumors for the study of primary pancreatic cancers has been unparalleled. 7, 9, 21, [25] [26] [27] Our ability to create xenograft enriched metastatic tumors will allow for similar study of the genetic events associated with advanced disease. The xenografted tumors we have established derived from metastases grew more rapidly than those derived from the matched primary carcinomas of the same patient (mean 4.0 months versus 5.4 months) suggesting the selection of neoplastic cell clones more autonomous in growth characteristics than those of the primary tumor counterparts. However, as xenografted tumors have been successfully grown from a large cohort of localized and surgically resectable pancreatic cancer, 7 the enhanced growth rate of these metastases may in part be reflective of their growth characteristics in vivo. At the very least, further studies to explore these differences are warranted. While numerous investigations have focused on the genetic alterations of primary infiltrating pancreatic cancers, few if any have addressed those events characteristic of advanced disease. Our findings of KRAS2 activating mutations in 82% and TP53 genetic inactivation in 55% of advanced carcinomas are consistent with rates reported previously, 14, 19, 20 and lend support to the genetic alteration of these two genes early in pancreatic carcinogenesis. In contrast, our data indicate that genetic inactivation of DPC4 is more prevalent in advanced stage metastatic disease than that reported for surgically resectable primary infiltrating pancreatic cancers, inactivated in 75% of the patients' metastatic cancers analyzed (p < 0.05). The increased rate of DPC4 inactivation in advanced disease lends further support to the prominent role of this tumor suppressor gene in the biology and aggressiveness of pancreatic cancer. Moreover, the data suggests that DPC4 inactivation continues to be selected for with tumor progression, a finding with important implications for anti-cancer therapies aimed at restoration of the TGF-β signal transduction pathway in this tumor type. 28 Of interest, in all cases we examined by immunohistochemical labeling, both the primary carcinoma and all matched metastases showed identical Dpc4 immunolabeling patterns (data not shown). While this finding may be interpreted as support for the hypothesis of an outgrowth of dominant metastatic clones within a primary tumor with successful spread to distant sites, 29 based on this data alone we cannot rule out the competing hypothesis that metastatic ability is inherent within a primary tumor. 30, 31 At the very least, our finding of a significant difference in the rate of Dpc4 loss of immunolabeling between primary and metastatic pancreatic cancer supports the use of this resource for the identification of cellular changes of biologic significance in advanced disease.
In summary, we provide initial data regarding the collection of high quality tissues from rapid autopsy participants of the GICR-MDP. The invaluable tissue resources generated by this program will provide an unparalleled resource for study of metastatic pancreatic cancer and of the metastatic process in general.
